bay3018250
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 15, 2024 (NCT06149520)
Timeline
Indications
Mechanism of action
- PlasminINHIBITOR
Plasmin inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06619483 | Phase 1 | Oct 9, 2024 | Bayer |
| NCT06562985 | Phase 1 | Sep 18, 2024 | Bayer |
| NCT06149520 | Phase 2 | Jan 15, 2024 | Bayer |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 3 | 3 | 2 | 2024 |
1 organizations
Page 1 / 1